IFP Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.3M | Sell |
52,930
-2,013
| -4% | -$433K | 0.24% | 85 |
|
|
2026
Q1 | $11.9M | Buy |
54,943
+11,677
| +27% | +$2.59M | 0.25% | 84 |
|
|
2025
Q4 | $9.89M | Sell |
43,266
-108
| -0.2% | -$24.6K | 0.22% | 90 |
|
|
2025
Q3 | $10M | Buy |
43,374
+287
| +0.7% | +$58.4K | 0.26% | 74 |
|
|
2025
Q2 | $8.05M | Buy |
43,087
+1,171
| +3% | +$218K | 0.23% | 87 |
|
|
2025
Q1 | $8.78M | Sell |
41,916
-1,333
| -3% | -$259K | 0.27% | 74 |
|
|
2024
Q4 | $7.69M | Buy |
43,249
+4,928
| +13% | +$906K | 0.25% | 82 |
|
|
2024
Q3 | $7.57M | Buy |
38,321
+6,264
| +20% | +$1.17M | 0.27% | 78 |
|
|
2024
Q2 | $5.5M | Buy |
32,057
+2,147
| +7% | +$356K | 0.22% | 101 |
|
|
2024
Q1 | $5.45M | Sell |
29,910
-1,251
| -4% | -$216K | 0.24% | 93 |
|
|
2023
Q4 | $4.83M | Sell |
31,161
-16,869
| -35% | -$2.46M | 0.23% | 95 |
|
|
2023
Q3 | $7.16M | Buy |
48,030
+1,299
| +3% | +$191K | 0.32% | 71 |
|
|
2023
Q2 | $6.3M | Buy |
46,731
+117
| +0.3% | +$17.2K | 0.26% | 79 |
|
|
2023
Q1 | $1.65M | Sell |
46,614
-20,283
| -30% | -$3.1M | 0.07% | 271 |
|
|
2022
Q4 | $2.49M | Sell |
66,897
-498
| -0.7% | -$76.4K | 0.07% | 316 |
|
|
2022
Q3 | $2.52M | Buy |
67,395
+6,188
| +10% | +$888K | 0.07% | 323 |
|
|
2022
Q2 | $2.29M | Hold |
61,207
| – | – | 0.07% | 311 |
|
|
2022
Q1 | $2.29M | Buy |
61,207
+17,724
| +41% | +$2.57M | 0.07% | 311 |
|
|
2021
Q4 | $5.89M | Sell |
43,483
-1,335
| -3% | -$158K | 0.12% | 100 |
|
|
2021
Q3 | $4.85M | Buy |
44,818
+5,820
| +15% | +$665K | 0.1% | 118 |
|
|
2021
Q2 | $4.39M | Buy |
38,998
+2,368
| +6% | +$267K | 0.09% | 126 |
|
|
2021
Q1 | $3.97M | Sell |
36,630
-289
| -0.8% | -$30.9K | 0.08% | 121 |
|
|
2020
Q4 | $3.96M | Buy |
36,919
+2,582
| +8% | +$248K | 0.16% | 99 |
|
|
2020
Q3 | $3.01M | Buy |
34,337
+4,352
| +15% | +$410K | 0.18% | 114 |
|
|
2020
Q2 | $2.89M | Buy |
29,985
+5,002
| +20% | +$440K | 0.23% | 92 |
|
|
2020
Q1 | $1.84M | Buy |
24,983
+464
| +2% | +$39.5K | 0.19% | 127 |
|
|
2019
Q4 | $2.19M | Buy |
24,519
+67
| +0.3% | +$5.56K | 0.16% | 148 |
|
|
2019
Q3 | $1.82M | Buy |
+24,452
| New | +$1.68M | 0.12% | 187 |
|
|
2019
Q1 | $767K | Sell |
9,568
-41,783
| -81% | -$3.42M | 0.1% | 204 |
|
|
2018
Q4 | $4.68M | Sell |
51,351
-13,473
| -21% | -$1.18M | 0.29% | 77 |
|
|
2018
Q3 | $6.13M | Buy |
64,824
+2,446
| +4% | +$232K | 0.25% | 86 |
|
|
2018
Q2 | $5.78M | Sell |
62,378
-14,344
| -19% | -$1.4M | 0.24% | 96 |
|
|
2018
Q1 | $7.42M | Hold |
76,722
| – | – | 0.34% | 63 |
|
|
2017
Q4 | $7.42M | Sell |
76,722
-32,893
| -30% | -$3.1M | 0.34% | 63 |
|
|
2017
Q3 | $9.74M | Sell |
109,615
-3,013
| -3% | -$229K | 0.39% | 49 |
|
|
2017
Q2 | $8.17M | Sell |
112,628
-5,909
| -5% | -$397K | 0.35% | 56 |
|
|
2017
Q1 | $7.72M | Buy |
118,537
+15,273
| +15% | +$960K | 0.34% | 61 |
|
|
2016
Q4 | $6.47M | Buy |
103,264
+35,458
| +52% | +$2.16M | 0.31% | 65 |
|
|
2016
Q3 | $4.28M | Sell |
67,806
-6,109
| -8% | -$395K | 0.22% | 94 |
|
|
2016
Q2 | $4.58M | Buy |
73,915
+64,347
| +673% | +$3.92M | 0.26% | 84 |
|
|
2016
Q1 | $767K | Sell |
9,568
-50,834
| -84% | -$2.83M | 0.1% | 204 |
|
|
2015
Q4 | $3.58M | Buy |
+60,402
| New | +$3.48M | 0.24% | 89 |
|
Other funds holding ABBV
IFP Advisors's ABBV Position: Q2 2026 in Review
IFP Advisors reduced its AbbVie (ABBV) stake by 3.7% in Q2 2026, selling an estimated $433K and leaving 52,930 shares worth $13.3M. The position accounts for 0.24% of the portfolio, ranked #85.
IFP Advisors first reported a position in ABBV in Q4 2015 and has held it in 42 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- IFP Advisors held 52,930 shares of AbbVie worth $13.3M as of Q2 2026.
- IFP Advisors sold 2,013 AbbVie shares in Q2 2026, an estimated $433K.
- AbbVie made up 0.24% of IFP Advisors's portfolio in Q2 2026, its #85 holding.
- IFP Advisors first reported a position in AbbVie in Q4 2015 and has held it in 42 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.